Amylyx Pharmaceuticals to Present Updates on its AMX0114 and

Amylyx Pharmaceuticals, Inc. today announced that two abstracts detailing next steps in the development of the Company’s investigational antisense oligonucleotide , AMX0114, for the potential...

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Japan , Massachusetts , United States , Orlando , Florida , Canada , , Muscular Dystrophy Association , Amylyx Pharmaceuticals Inc , Linkedin , Exchange Commission , Nasdaq , Twitter , Amylyx Pharmaceuticals , Scientific Conference , Next Steps , Critical Effector , Axonal Degeneration , Findings From , Pharmacodynamic Study , Sodium Phenylbutyrate , Participants With Amyotrophic Lateral Sclerosis , Safety Information , Enterohepatic Circulation Disorders , Pancreatic Disorders , Patients Sensitive , High Sodium , Private Securities Litigation Reform Act , Amylyx United States Securities , Amylyx Quarterly Report , Markets ,